Article date: February 2007
By: M D Tricklebank in Volume 150, Issue 4, pages 381-382
The discovery of JP‐1302 as a selective, high affinity antagonist at the α2C‐adrenoceptor will enable researchers to probe the functional role and address the therapeutic utility of this potentially highly important adrenoceptor subtype.
British Journal of Pharmacology (2007) 150, 381–382. doi:10.1038/sj.bjp.0707007
DOI: 10.1038/sj.bjp.0707007
View this article